GNT Pharma 
Welcome,         Profile    Billing    Logout  
 1 Product   3 Diseases  1 Product   2 Trials   30 News 
9 Trials

   

 
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
Encelto (revakinagene taroretcel-lwey) / Neurotech Pharma
NCT06971939: Phase 4 Study: Long-term Safety and Efficacy of NT-501 in MacTel Type 2, Including Sham Procedure Participants

Not yet recruiting
4
285
Europe, US, RoW
NT-501/revakinagene taroretcel-lwey, ENCELTO
Neurotech Pharmaceuticals
Macular Telangiectasia Type 2 (MacTel)
06/30
06/30
NCT03316300 / 2017-003234-82: A Study to Determine the Safety and Efficacy of NT-501 in Macular Telangiectasia Type 2 - Protocol A

Completed
3
120
Europe, US, RoW
NT-501, Sham Procedure
Neurotech Pharmaceuticals, The Lowy Medical Research Institute Limited
Macular Telangiectasia Type 2 (MacTel)
08/22
09/22
NCT03319849 / 2017-003260-12: A Study to Determine the Safety and Efficacy of NT-501 in Macular Telangiectasia Type 2 - Protocol B

Completed
3
119
Europe, US, RoW
NT-501, Sham
Neurotech Pharmaceuticals, The Lowy Medical Research Institute Limited
Macular Telangiectasia Type 2
08/22
09/22
NCT06397131: A Study to Determine the Safety and Efficacy of NT-501 With MHFM

Active, not recruiting
3
12
US
NT-501 CNTF Implant
Neurotech Pharmaceuticals
Macular Telangiectasia Type 2
04/26
07/26
NCT04729972: Safety Study to Evaluate Bilateral CNTF Implants in Subjects With MacTel Type 2

Completed
2
33
US, RoW
NT-501 CNTF implant
Neurotech Pharmaceuticals, The Lowy Medical Research Institute Limited
Macular Telangiectasia Type 2
12/22
12/22
NCT02862938 / 2011-004177-83: Study of NT-501 Encapsulated Cell Therapy for Glaucoma Neuroprotection and Vision Restoration

Active, not recruiting
2
54
US
NT-501 ECT implant, Sham
Stanford University
Glaucoma
08/25
12/25
NCT04577300: Dual Intravitreal Implantation of NT-501 Encapsulated Cell Therapy for Glaucoma

Recruiting
2
30
US
NT-501, Sham comparator
Stanford University
Glaucoma
08/25
12/25
nelonemdaz (Neu2000KL) / Zhejiang Apeloa Medical Technology
RODIN, NCT05041010: Rescues On Reperfusion Damage In Cerebral Infarction by Nelonemdaz

Recruiting
3
496
RoW
Neu2000KWL group, Placebo group
GNT Pharma
Ischemic Stroke
06/24
01/25
ChiCTR2200059163: A randomized, blind, placebo-parallel, multicenter phase III clinical study, to assess the efficacy and safety of using Salfaprodil for injection initiated within 8 hours of onset of acute ischemic stroke in subjects undergoing intravenous thrombolytic therapy

Recruiting
3
948
 
Drug therapy ;Placebo
Beijing Tiantan Hospital, Capital Medical University; Beijing Tiantan Hospital, Capital Medical University, Sponsor Self-financing
acute ischemic stroke
 
 
flusalazine (ND-07) / GNT Pharma
No trials found
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
Encelto (revakinagene taroretcel-lwey) / Neurotech Pharma
NCT06971939: Phase 4 Study: Long-term Safety and Efficacy of NT-501 in MacTel Type 2, Including Sham Procedure Participants

Not yet recruiting
4
285
Europe, US, RoW
NT-501/revakinagene taroretcel-lwey, ENCELTO
Neurotech Pharmaceuticals
Macular Telangiectasia Type 2 (MacTel)
06/30
06/30
NCT03316300 / 2017-003234-82: A Study to Determine the Safety and Efficacy of NT-501 in Macular Telangiectasia Type 2 - Protocol A

Completed
3
120
Europe, US, RoW
NT-501, Sham Procedure
Neurotech Pharmaceuticals, The Lowy Medical Research Institute Limited
Macular Telangiectasia Type 2 (MacTel)
08/22
09/22
NCT03319849 / 2017-003260-12: A Study to Determine the Safety and Efficacy of NT-501 in Macular Telangiectasia Type 2 - Protocol B

Completed
3
119
Europe, US, RoW
NT-501, Sham
Neurotech Pharmaceuticals, The Lowy Medical Research Institute Limited
Macular Telangiectasia Type 2
08/22
09/22
NCT06397131: A Study to Determine the Safety and Efficacy of NT-501 With MHFM

Active, not recruiting
3
12
US
NT-501 CNTF Implant
Neurotech Pharmaceuticals
Macular Telangiectasia Type 2
04/26
07/26
NCT04729972: Safety Study to Evaluate Bilateral CNTF Implants in Subjects With MacTel Type 2

Completed
2
33
US, RoW
NT-501 CNTF implant
Neurotech Pharmaceuticals, The Lowy Medical Research Institute Limited
Macular Telangiectasia Type 2
12/22
12/22
NCT02862938 / 2011-004177-83: Study of NT-501 Encapsulated Cell Therapy for Glaucoma Neuroprotection and Vision Restoration

Active, not recruiting
2
54
US
NT-501 ECT implant, Sham
Stanford University
Glaucoma
08/25
12/25
NCT04577300: Dual Intravitreal Implantation of NT-501 Encapsulated Cell Therapy for Glaucoma

Recruiting
2
30
US
NT-501, Sham comparator
Stanford University
Glaucoma
08/25
12/25
nelonemdaz (Neu2000KL) / Zhejiang Apeloa Medical Technology
RODIN, NCT05041010: Rescues On Reperfusion Damage In Cerebral Infarction by Nelonemdaz

Recruiting
3
496
RoW
Neu2000KWL group, Placebo group
GNT Pharma
Ischemic Stroke
06/24
01/25
ChiCTR2200059163: A randomized, blind, placebo-parallel, multicenter phase III clinical study, to assess the efficacy and safety of using Salfaprodil for injection initiated within 8 hours of onset of acute ischemic stroke in subjects undergoing intravenous thrombolytic therapy

Recruiting
3
948
 
Drug therapy ;Placebo
Beijing Tiantan Hospital, Capital Medical University; Beijing Tiantan Hospital, Capital Medical University, Sponsor Self-financing
acute ischemic stroke
 
 
flusalazine (ND-07) / GNT Pharma
No trials found

Download Options